Published in Ann Transl Med on March 01, 2016
Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors | NCT01324479
Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer | NCT02219711
A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer | NCT02019693
MET/HGF pathway activation as a paradigm of resistance to targeted therapies. Ann Transl Med (2017) 0.75
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A (2007) 11.85
Comprehensive molecular profiling of lung adenocarcinoma. Nature (2014) 11.02
Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science (1991) 8.68
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature (1984) 5.85
Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol (2013) 5.21
The human met oncogene is related to the tyrosine kinase oncogenes. Nature (1985) 3.46
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol (2011) 3.27
Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res (2006) 3.12
CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev (2002) 3.07
Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet (1998) 2.50
Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer (2008) 2.06
Hepatocyte growth factor/scatter factor is a motogen for interneurons migrating from the ventral to dorsal telencephalon. Neuron (2001) 2.03
Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov (2015) 1.91
Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers. J Thorac Oncol (2009) 1.81
Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov (2015) 1.67
Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res (1998) 1.66
c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. Cancer Sci (2007) 1.33
Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations. J Clin Oncol (2015) 1.26
HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors. Oncogene (2012) 1.20
c-MET/phospho-MET protein expression and MET gene copy number in non-small cell lung carcinomas. J Thorac Oncol (2012) 1.06
MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung. Clin Cancer Res (2014) 1.05
Response to Crizotinib in a Patient With Lung Adenocarcinoma Harboring a MET Splice Site Mutation. Clin Lung Cancer (2015) 0.93
Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing. Lung Cancer (2014) 0.89
MET Mutation Associated with Responsiveness to Crizotinib. J Thorac Oncol (2015) 0.87
MET-Mutated NSCLC with Major Response to Crizotinib. J Thorac Oncol (2015) 0.86
MET expression and copy number heterogeneity in nonsquamous non-small cell lung cancer (nsNSCLC). Oncotarget (2015) 0.84
Profiling of Oncogenic Driver Events in Lung Adenocarcinoma Revealed MET Mutation as Independent Prognostic Factor. J Thorac Oncol (2015) 0.77